Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SF2a-TT15 vaccine for Shigella flexneri 2a prevention
NCT04078022Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Mar 2020
- Primary completion
- Jan 2023
- Modality
- Bivalent/Multivalent Binders, Recombinant Proteins and Enzymes, Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of SF2a-TT15 in shigellosis, sponsored by University of Maryland, Baltimore. Started Mar 2020; status: completed.
02
Drugs
SF2a-TT15
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT04078022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04078022.